You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
泰格医药(300347.SZ):拟出资5000万元投资阿斯利康中金医疗基金
格隆汇 08-28 22:03

格隆汇 8 月 28日丨泰格医药(300347.SZ)公告,公司投资平台杭州泰格股权投资合伙企业(有限合伙)拟以自有资金投资AstraZeneca-CICC基金(暂定名,以后续工商登记为准,以下简称“合伙企业”)。合伙企业认缴出资总额预计为人民币25亿元,公司将作为该合伙企业的有限合伙人(LP)认缴出资额为人民币5000万元。

本次投资主体杭州泰格股权投资合伙企业(有限合伙)成立于2016年4月22日,系本公司专业投资平台,由两名合伙人共同发起设立,执行事务合伙人为上海泰格医药科技有限公司,有限合伙人为杭州泰格医药科技股份有限公司。

根据公司章程及相关制度规定,本次投资已经过公司第四届董事会第五次会议审议通过。本次对外投资事项不构成关联交易,不构成《上市公司重大资产重组管理办法》规定的重大资产重组。本次投资的资金来源为自有资金。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account